WASHINGTON, DC (WWLP) – The Federal Trade Commission (FTC) has issued cease and desist warning letters to ten companies suspected of advertising unproven treatments or cures for diabetes, ordering the companies to stop making unsubstantiated claims within 15 days or face potential legal action by the FTC.
The FTC demands were issued jointly with U.S. Food and Drug Administration (FDA) warning letters, in which the FDA warned the companies that their diabetes products are both unapproved and misbranded, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
“Out-of-control insulin prices are driving Americans to turn to questionable products rather than proven treatments,” said Samuel Levine, Acting Director of the FTC’s Bureau of Consumer Protection. “The FTC and FDA are joining forces to call out 10 companies for selling supposed diabetes treatments that don’t appear to be supported by sound science.”
The letter demands the companies “stop making any claim that a product can prevent, treat, or cure diabetes without the required scientific evidence, or potentially face legal action by the Commission.” The companies were also warned that “marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation.” The companies have 15 working days to respond with what actions they have taken to rectify the situation.
The FTC’s cease and desist demands were issued to the following companies: 1) Ar-Rahmah Pharm, LLC; 2) Aceva, LLC; 3) Live Good Inc.; 4) Holistic Healer & Wellness Center, Inc.; 5) Lysulin, Inc.; 6) Metamune Inc.; 7) Nuturna International LLC; 8) Pharmaganics LLC; 9) Phytag Labs; and 10) Radhanite, LLC d/b/a Curalife Ltd.